Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

3 terminated/withdrawn out of 12 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

50%

6 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

6(75.0%)

N/A

2(25.0%)

8Total

Phase 4(6)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT03976544Phase 4Terminated

Natural Cycle Versus Hormone Replacement Therapy Cycle for a Frozen-thawed Embryo Transfer in PGT Patients

Role: lead

NCT04758871Phase 4Completed

Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles

Role: lead

NCT03846544Phase 4Completed

Double Pick up in Poor Prognosis Women

Role: lead

NCT04997070Completed

Sperm Selection Using Microfluidic Technology

Role: lead

NCT05405686Phase 4Withdrawn

Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders

Role: lead

NCT05521828Not ApplicableRecruiting

Luteal Phase Ovarian Stimulation With Follitropin Delta and Dydrogesterone

Role: lead

NCT05746793Recruiting

At High-risk for Pre-eclampsia After Assisted Reproductive Technology

Role: lead

NCT04425317Not ApplicableCompleted

Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients

Role: lead

NCT04002635Phase 4Withdrawn

Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS)

Role: lead

NCT04665102Unknown

Pilot Study on Deep Learning in the Eye

Role: lead

NCT03677336Phase 4Completed

Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI

Role: lead

NCT03390205Unknown

OCT Angiography in Vitreo and Chorioretinal Pathologies

Role: lead

All 12 trials loaded